// App-Quantinova.ai

PB1698 : DREAMM-5 PLATFORM TRIAL: BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH FIVE DIFFERENT NOVEL AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Researchers

Presenter

  • Paul G Richardson

Principal Investigators

  • Natalie Callander

  • Ajay Nooka

  • Kevin Song

  • Katarina Uttervall

  • Monique C. Minnema

  • Paula Rodriguez-Otero

  • David Routledge

  • Josephine Khan

  • Herbert Struemper

  • Anne Yeakey

  • Rocio Montes de Oca

  • L. Mary Smith

  • Nicola Jackson

  • Morrys Kaisermann

  • Ellie Im

  • Christoph M. Ahlers

  • Beata Holkova

  • Ira Gupta

  • Brandon E. Kremer

  • Hang Quach

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Karolinska University Hospital, Stockholm, Sweden

  • Department of Hematology, UMC Utrecht Cancer Center, Utrecht, Netherlands

  • Vancouver General Hospital, Vancouver, BC, Canada

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • St. Vincent’s Hospital Melbourne,University of Melbourne,Melbourne,Australia

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Carbone Cancer Center, University of Wisconsin,Madison, WI,United States

  • SpringWorks Therapeutics Inc,Stamford, CT,United States

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • GlaxoSmithKline, Stockley Park, United Kingdom

  • Sanofi Genzyme, Cambridge, MA, United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • GlaxoSmithKline, Upper Providence, PA, United States.

  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

  • GlaxoSmithKline,Chapel Hill,United States

  • GlaxoSmithKline, Stevenage, United Kingdom.

Locations

  • Canada

  • Sweden

  • Netherlands

  • United States

  • Australia

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • GSK2857916

  • PF-03084014

  • Dostarlimab

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cohort

Phase

  • NA

Study Id's

  • NCT03525678

  • NCT04126200

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved